Literature DB >> 11010606

The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data.

B Jonsson1, B Nilsson.   

Abstract

OBJECTIVE: To quantify sick leave and medical retirement for the year 1989 in adults with a history of nonsecreting pituitary adenoma. DESIGN AND
SETTING: A cross-sectional analysis of official Swedish data from 1989 was performed. Sick leave and disability pension data for these patients were obtained from the Swedish National Social Insurance Board, which also supplied information on sick leave taken by an age- and gender-matched control population of 5121 individuals. Uptake of disability pensions and the reasons for drawing these pensions in the study group were compared with national statistics. STUDY POPULATION: A group of 809 eligible adults with nonsecreting pituitary adenoma was identified from the national cancer registry. MAIN OUTCOME MEASURES AND
RESULTS: Almost a quarter of the patients with a history of pituitary adenoma had retired due to ill health (23.8%); this was twice the figure expected from national statistics (11.5%). Similar results were obtained when men and women were considered separately. Some patients (17%) had received disability pensions before the diagnosis of pituitary adenoma, but the majority (75%) retired on medical grounds at least 1 year after their diagnosis. The reasons for early retirement in the study group were largely related to the diagnosis of pituitary adenoma (e.g. neoplasm, endocrine disorders), but there was some evidence of an increase in the number of disability pensions awarded because of diseases of the nervous system and sensory organs. Patients with a history of pituitary adenoma took significantly more sick leave in 1989 than those in the control group (mean 40.2 vs 24.0 days), and this significant difference applied to both sexes.
CONCLUSIONS: A cross-sectional analysis of Swedish national data from 1989 showed excess morbidity, relative to reference data, in patients with a history of nonsecreting pituitary adenoma. Suboptimal conventional hormone replacement therapy and untreated growth hormone deficiency might to some extent explain the increased morbidity found in the present study.

Entities:  

Mesh:

Year:  2000        PMID: 11010606     DOI: 10.2165/00019053-200018010-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency.

Authors:  G A McGauley
Journal:  Acta Paediatr Scand Suppl       Date:  1989

2.  Body composition in growth hormone-deficient adults.

Authors:  A Binnerts; P Deurenberg; G R Swart; J H Wilson; S W Lamberts
Journal:  Am J Clin Nutr       Date:  1992-05       Impact factor: 7.045

3.  An approximate distribution of estimates of variance components.

Authors:  F E SATTERTHWAITE
Journal:  Biometrics       Date:  1946-12       Impact factor: 2.571

4.  Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality.

Authors:  B Nilsson; E Gustavasson-Kadaka; B A Bengtsson; B Jonsson
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

5.  Decreased psychological well-being in adult patients with growth hormone deficiency.

Authors:  T Rosén; L Wirén; L Wilhelmsen; I Wiklund; B A Bengtsson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-01       Impact factor: 3.478

6.  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.

Authors:  V Markussis; S A Beshyah; C Fisher; P Sharp; A N Nicolaides; D G Johnston
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

7.  Reduced bone mineral content in adult patients with growth hormone deficiency.

Authors:  T Rosén; T Hansson; H Granhed; J Szucs; B A Bengtsson
Journal:  Acta Endocrinol (Copenh)       Date:  1993-09

8.  High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.

Authors:  J O Johansson; K Landin; L Tengborn; T Rosén; B A Bengtsson
Journal:  Arterioscler Thromb       Date:  1994-03

9.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

10.  Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.

Authors:  P Kann; B Piepkorn; B Schehler; J Andreas; J Lotz; W Prellwitz; J Beyer
Journal:  Clin Endocrinol (Oxf)       Date:  1998-05       Impact factor: 3.478

View more
  6 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Medical management of hypopituitarism in patients with pituitary adenomas.

Authors:  Baha M Arafah
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 3.  Circulating Noncoding RNAs in Pituitary Neuroendocrine Tumors-Two Sides of the Same Coin.

Authors:  Henriett Butz
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

4.  Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.

Authors:  Haroon Hasan; Fuchsia Howard; Steven G Morgan; Daniel L Metzger; Andrea C Lo; Karen Goddard; Sabrina Gill; Michelle Johnson
Journal:  Healthc Policy       Date:  2014-02

5.  The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden.

Authors:  Kristian Bolin; Rickard Sandin; Maria Koltowska-Häggström; Jane Loftus; Christin Prütz; Björn Jonsson
Journal:  Cost Eff Resour Alloc       Date:  2013-09-30

6.  Work disability and its determinants in patients with pituitary tumor-related disease.

Authors:  Daniel J Lobatto; Anath N V Steffens; Amir H Zamanipoor Najafabadi; Cornelie D Andela; Alberto M Pereira; Wilbert B van den Hout; Wilco C Peul; Thea P M Vliet Vlieland; Nienke R Biermasz; Wouter R van Furth
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.